Head-to-head
Ro (Ro Body) vs Direct Meds
Compared on both medications across the eight dimensions this database records. They differ on 5 of those eight. Direct Meds is cheaper on all-in tirzepatide at 10 mg/week, though on a flat-versus-tiered matchup the cheaper program can change further up the dose ladder.
The short answer
Ro (Ro Body) is $747 a month all-in for tirzepatide; Direct Meds is $399. Over twelve months that is $8,964 against $4,788. Value Scores are 26.3 and 45.1 out of 100.
Tirzepatide
Plan pages: Ro (Ro Body) plans · Direct Meds plans
At 10 mg/week, Ro (Ro Body) is $747 a month all-in and Direct Meds is $399 — $348 apart, or $4,176 across a year. Over twelve months the totals are $8,964 (billed monthly) and $4,788 (billed monthly).
Ro (Ro Body) prices tirzepatide by dose: $448 per month at 2.5 mg rising to $598 at 10 mg, a difference of $150 a month between the bottom and top of the ladder. The company publishes no price at 5, 7.5, 12.5, 15 mg, so those doses are left blank rather than estimated.
Direct Meds prices tirzepatide by dose: $299 per month at 2.5 mg rising to $399 at 10 mg, a difference of $100 a month between the bottom and top of the ladder. The company publishes no price at 5, 7.5, 12.5, 15 mg, so those doses are left blank rather than estimated.
| Dose | Ro (Ro Body) | Rank | Direct Meds | Rank | Cheaper |
|---|---|---|---|---|---|
| 2.5 mg | $448 | 29/31 | $299 | 17/31 | Direct Meds by $149 |
| 5 mg | — | — | — | — | neither publishes |
| 7.5 mg | — | — | — | — | neither publishes |
| 10 mg | $598 | 27/27 | $399 | 20/27 | Direct Meds by $199 |
| 12.5 mg | — | — | — | — | neither publishes |
| 15 mg | — | — | — | — | neither publishes |
Direct Meds is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Across the 27 programs this database can rank on tirzepatide, Ro (Ro Body) sits 27 of 27 on all-in monthly cost and Direct Meds sits 22. There are 4 other programs priced between them. The field median is $339 and the floor is $169, so both sit above the median. Ro (Ro Body) is $578 above the cheapest tirzepatide program on record. Direct Meds is $230 above the cheapest tirzepatide program on record.
LillyDirect (Zepbound), the lowest FDA-approved tirzepatide channel here, is $449 a month — Ro (Ro Body) undercuts it by $-298, Direct Meds by $50. Compounded products are not FDA approved; insurance can reverse that comparison.
| Plan term | Ro (Ro Body) | Direct Meds | Cheaper |
|---|---|---|---|
| Month to month | $598 | $399 | Direct Meds by $199 |
| Settled dose | Ro (Ro Body) | Direct Meds | Difference |
|---|---|---|---|
| 2.5 mg | $7,164 | $3,588 | $3,576 apart |
| 10 mg | $8,964 | $4,788 | $4,176 apart |
Ro (Ro Body) publishes no rate for 3-month term, 6-month term, 12-month term; Direct Meds publishes none for 3-month term, 6-month term, 12-month term. An unpublished term is not necessarily unavailable — it is unpriced in public, which you can only resolve by asking.
A titration year is not twelve months at the maintenance price. Stepping up roughly four weeks per dose before settling at 10 mg/week, the first twelve months work out to $8,814 on Ro (Ro Body) and $4,688 on Direct Meds — $4,126 apart, and a different gap from the $4,176 you would get by multiplying the monthly difference by twelve. The ramp is cheaper than the settled rate on whichever program prices by dose, which is why a first-year quote and a steady-state quote are not the same number.
That calculation is partial: Ro (Ro Body) publishes no price at 2 of the 6 doses and Direct Meds publishes no price at 2 of them, so the maintenance rate stands in for the missing steps rather than a number the company has stated.
Value Scores are 26.3 for Ro (Ro Body) and 45.1 for Direct Meds, against a tirzepatide category floor of $169. Direct Meds leads by 18.8 points, driven mostly by price.
| Program | Price /70 | Evidence /15 | Dose /10 | Membership /5 | Total /100 |
|---|---|---|---|---|---|
| Ro (Ro Body) | 15.8 | 10.5 | 0 | 0 | 26.3 |
| Direct Meds | 29.6 | 10.5 | 0 | 5 | 45.1 |
Semaglutide
Plan pages: Ro (Ro Body) plans · Direct Meds plans
At 2.4 mg/week, Ro (Ro Body) is $647 a month all-in and Direct Meds is $297 — $350 apart, or $4,200 across a year. Over twelve months the totals are $7,764 (billed monthly) and $3,564 (billed monthly).
Ro (Ro Body) prices semaglutide by dose: $298 per month at 0.25 mg rising to $498 at 2.4 mg, a difference of $200 a month between the bottom and top of the ladder. The company publishes no price at 0.5, 1, 1.7 mg, so those doses are left blank rather than estimated.
Direct Meds prices semaglutide by dose: $249 per month at 0.25 mg rising to $297 at 2.4 mg, a difference of $48 a month between the bottom and top of the ladder. The company publishes no price at 0.5, 1, 1.7 mg, so those doses are left blank rather than estimated.
Direct Meds is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Value Scores are 24.5 for Ro (Ro Body) and 45.9 for Direct Meds, against a semaglutide category floor of $129. Direct Meds leads by 21.4 points, driven mostly by price.
Where the two programs differ
All-in monthly
Direct Meds is cheaper month to month — $399 against $747, a gap of $348 every month, or $4,176 across a year if both rates hold.
Cancellation terms
Cancellation differs: Ro (Ro Body) states Cancel anytime, while Direct Meds states Per provider terms. Read this next to the twelve-month figures — a prepaid discount and a restrictive refund policy are the same decision.
Commitment
Ro (Ro Body) asks for Membership month-to-month ($39 first month; ~$74/mo prepaid annual); Direct Meds asks for Monthly (no commitment indicated). This is the dimension most likely to change which program is actually cheaper for you, because the lowest rates on both sides are usually attached to the longest terms.
Membership fee
Ro (Ro Body) charges a membership of $149 a month on top of the medication. That is already folded into the all-in figures above — it is broken out here because a membership is a recurring charge that continues even in a month you skip a shipment.
Twelve-month cost
Over twelve months the totals are $8,964 for Ro (Ro Body) and $4,788 for Direct Meds. Direct Meds is lower by $4,176 — a figure worth checking against the cancellation terms below, because a prepaid year is only cheaper if you stay on it.
Dose policy
Both price by dose, so both advertised figures understate the cost of a titration year. Compare the ladders above rather than the headline rates.
Evidence status
Both figures carry the same evidence status, reported: sourced from dated third-party reporting; first-party capture pending. Neither is stronger than the other on provenance.
Shipping
Shipping is handled the same way by both — included in the quoted price.
What each record says
Ro (Ro Body) Official site
Ro exited compounded GLP-1s in 2026 and now pairs a $39-then-$149/month membership (about $74/month prepaid annually) with brand-only medication: Wegovy pill from $149, Wegovy pen from $199 promotional / $349 standard, and Zepbound from $299 to $449 by dose. Its insurance concierge — benefits checks, prior authorizations, appeals — is the strongest in the category and can take a covered patient to a $25 copay.
It names its compounding pharmacy — Brand fulfillment via NovoCare / LillyDirect pathways, recorded as Brand channel + insurance concierge — which can be checked against state board licensing and FDA inspection records before you order; commitment terms are Membership month-to-month ($39 first month; ~$74/mo prepaid annual); cancellation is Cancel anytime; availability is stated as 50 states.
Evidence: reported — sourced from dated third-party reporting; first-party capture pending, captured . Source — Ro pricing pages as reported Jul 2026 ($149 membership + Zepbound $299–$449 by dose); first-party checkout capture pending
Watch: Cash-pay all-in runs ~$448–$598/month at maintenance; Ro's value case is insurance navigation, not cash price.
Direct Meds Official site
Direct Meds offers compounded GLP-1s in multiple formats — sublingual and injectable — with all-inclusive pricing verified on its own product pages. Semaglutide runs $249–$297/mo and tirzepatide $299–$399/mo depending on format; the lower figures are for sublingual delivery.
It does not publicly name its compounding pharmacy; the record shows Partner 503A pharmacy (not publicly named), so who actually makes the medication cannot be independently verified; commitment terms are Monthly (no commitment indicated); cancellation is Per provider terms; availability is stated as Confirm at intake.
Evidence: reported — sourced from dated third-party reporting; first-party capture pending, captured . Source — rangeyourself.com, Direct Meds product pages verified 2026-07-25
Watch: Pricing varies by format and page; product-page 'all-inclusive' rates differ from homepage promo cards. Rank is based on injectable rate as primary. Reported status — RangeYourself verified 2026-07-25 on Direct Meds' own product pages.
What neither record tells you
Ro (Ro Body) does not publish
- no tirzepatide price at 5, 7.5, 12.5, 15 mg per week
- no published twelve-month tirzepatide rate
- no semaglutide price at 0.5, 1, 1.7 mg per week
- no published twelve-month semaglutide rate
Direct Meds does not publish
- no tirzepatide price at 5, 7.5, 12.5, 15 mg per week
- no published twelve-month tirzepatide rate
- no semaglutide price at 0.5, 1, 1.7 mg per week
- no published twelve-month semaglutide rate
- no named compounding pharmacy
- no state-by-state availability list — it says Confirm at intake
- no specific cancellation or refund terms
Ask Ro (Ro Body) and Direct Meds for each of those in writing before enrolling. A gap is not evidence of a problem; it does mean nothing can be checked against it.
What would change this answer
Evidence may be upgraded. Ro (Ro Body), Direct Meds carry a price we have not captured at checkout. A capture would move the evidence term and could reorder these two without any price changing.
Which one suits which reader
On the lowest standing monthly rate for tirzepatide, Direct Meds Official site wins this matchup. If you want to be able to pause without still paying, direct meds carries no membership.
Both figures should be checked at the provider's own checkout before you pay. Ro (Ro Body)'s tirzepatide price is reported as of 2026-08-11; Direct Meds's is reported as of 2026-07-25.
Questions
Is Ro (Ro Body) or Direct Meds cheaper for tirzepatide?
Direct Meds is cheaper on all-in monthly cost at 10 mg/week: $399 against $747, a difference of $348 a month. All-in means the medication plus every mandatory recurring fee.
What is the twelve-month cost of Ro (Ro Body) versus Direct Meds?
Ro (Ro Body) works out to $8,964 across twelve months and Direct Meds to $4,788, on the plan terms each publishes.
Does Ro (Ro Body) or Direct Meds raise the price as the dose goes up?
Ro (Ro Body): yes, it prices by dose. Direct Meds: yes, it prices by dose. Where one program is flat and the other is tiered, the cheaper of the two can change as you titrate upward.
How many ways do Ro (Ro Body) and Direct Meds differ?
5 of the eight dimensions this site records: all-in monthly, twelve-month cost, dose policy, membership, shipping, commitment, cancellation terms and evidence status.
Which of Ro (Ro Body) and Direct Meds names its pharmacy?
Ro (Ro Body) does — Brand fulfillment via NovoCare / LillyDirect pathways. Direct Meds does not, recording only Partner 503A pharmacy (not publicly named), so who makes its medication cannot be independently verified.
How well evidenced are the Ro (Ro Body) and Direct Meds prices?
Ro (Ro Body)'s tirzepatide figure is reported — sourced from dated third-party reporting; first-party capture pending — captured 2026-08-11. Direct Meds's is reported, captured 2026-07-25. Evidence status is worth fifteen points in the Value Score, so it is priced in rather than mentioned as an aside.
Which is cheaper for semaglutide?
Direct Meds, at $297 a month all-in against $647 at 2.4 mg/week. The two programs do not necessarily lead on both medications.
Official sources: Ro (Ro Body) official site · Direct Meds official site. Compounded tirzepatide and semaglutide are not FDA-approved products.